Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Highly versatile polyelectrolyte complexes for improving the enzyme replacement therapy of lysosomal storage disorders

  • Giannotti, M. I.
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Oliva, Mireia
  • Andrade, Fernanda|||0000-0002-4947-2346
  • García Aranda, Natalia|||0000-0003-3230-9881
  • Melgarejo, Marta
  • Pulido, Daniel|||0000-0002-2841-194X
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Fernández Caparrós, Yolanda
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Royo, Miriam|||0000-0001-5292-0819
  • García Parajó, María F..
  • Sanz, Fausto
  • Schwartz, Simon|||0000-0001-8297-7971
Lysosomal storage disorders are currently treated by enzyme replacement therapy (ERT) through the direct administration of the unprotected recombinant protein to the patients. Herein we present an ionically crosslinked polyelectrolyte complex (PEC) composed of trimethyl chitosan (TMC) and -galactosidase A (GLA), the defective enzyme in Fabry disease, with the capability of directly targeting endothelial cells by incorporating peptide ligands containing the RGD sequence. We assessed the physicochemical properties, cytotoxicity and hemocompatibility of RGD-targeted and un-targeted PECs, the uptake by endothelial cells and the intracellular activity of PECs in cell culture models of Fabry disease. Moreover, we also explored the effect of different freezedrying procedures in the overall activity of the PECs. Our results indicate that the use of integrin-binding RGD moiety within the PEC increases their uptake and the efficacy of the GLA enzyme, while the freeze-drying allows keeping intact the activity of the therapeutic protein. Overall, these results highlight the potential of TMC-based PECs as a highly versatile and feasible drug delivery system for improving the ERT of lysosomal storage disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Illuminating phenylazopyridines to photoswitch metabotropic glutamate receptors, from the flask to the animals

  • Gómez-Santacana, Xavier|||0000-0001-8830-0494
  • Pittolo, Silvia|||0000-0002-5673-1692
  • Rovira, Xavier|||0000-0002-9764-9927
  • Lopez, Marc
  • Zussy, Charleine
  • Dalton, James A. R.|||0000-0002-5279-4581
  • Faucherre, Adèle
  • Jopling, Chris
  • Pin, Jean-Philippe|||0000-0002-1423-345X
  • Ciruela, Francisco|||0000-0003-0832-3739
  • Goudet, Cyril|||0000-0002-8255-3535
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Gorostiza, Pau|||0000-0002-7268-5577
  • Llebaria, Amadeu|||0000-0002-8200-4827
Phenylazopyridines are photoisomerizable compounds with high potential to control biological functions with light. We have obtained a series of phenylazopyridines with light dependent activity as negative allosteric modulators (NAM) of metabotropic glutamate receptor subtype 5 (mGlu). Here we describe the factors needed to achieve an operational molecular photoisomerization and its effective translation into in vitro and in vivo receptor photoswitching, which includes zebrafish larva motility and the regulation of the antinociceptive effects in mice. The combination of light and some specific phenylazopyridine ligands displays atypical pharmacological profiles, including light-dependent receptor overactivation, which can be observed both in vitro and in vivo. Remarkably, the localized administration of light and a photoswitchable compound in the peripheral tissues of rodents or in the brain amygdalae results in an illumination-dependent analgesic effect. The results reveal a robust translation of the phenylazopyridine photoisomerization to a precise photoregulation of biological activity. The cis - trans photoisomerization of phenylazopyridines, allowing mGlu receptor activity photoswitching in cells, is used in vivo to control zebrafish motility with light and analgesia in mice including peripheral and brain localized illumination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Photomodulation of G protein-coupled adenosine receptors by a novel light-switchable ligand

  • Bahamonde, María Isabel
  • Taura, Jaume
  • Paoletta, Silvia
  • Gakh, Anadrei A.
  • Chakraborty, Saibal
  • Hernando, Jordi|||0000-0002-1126-4138
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Jacobson, Kenneth A.|||0000-0001-8104-1493
  • Gorostiza, Pau|||0000-0002-7268-5577
  • Ciruela, Francisco|||0000-0003-0832-3739
The adenosinergic system operates through G protein-coupled adenosine receptors, which have become promising therapeutic targets for a wide range of pathological conditions. However, the ubiquity of adenosine receptors and the eventual lack of selectivity of adenosine-based drugs have frequently diminished their therapeutic potential. Accordingly, here we aimed to develop a new generation of light-switchable adenosine receptor ligands that change their intrinsic activity upon irradiation, thus allowing the spatiotemporal control of receptor functioning (i.e., receptor activation/inactivation dependent on location and timing). Therefore, we synthesized an orthosteric, photoisomerizable, and nonselective adenosine receptor agonist, nucleoside derivative MRS5543 containing an aryl diazo linkage on the N substituent, which in the dark (relaxed isomer) behaved as a full adenosine A receptor (AR) and partial adenosine A receptor (AR) agonist. Conversely, upon photoisomerization with blue light (460 nm), it remained a full AR agonist but became an AR antagonist. Interestingly, molecular modeling suggested that structural differences encountered within the third extracellular loop of each receptor could modulate the intrinsic, receptor subtype-dependent, activity. Overall, the development of adenosine receptor ligands with photoswitchable activity expands the pharmacological toolbox in support of research and possibly opens new pharmacotherapeutic opportunities.